-
公开(公告)号：EP1448201A2
公开(公告)日：2004-08-25
申请号：EP02781293.2
申请日：2002-10-28
申请人： Merck Patent GmbH
CPC分类号： A61K31/496
摘要： The invention relates to the use of compounds of formula (I), wherein R?1, R2, R4 and R5¿ have the designations cited in patent claim 1, and to the physiologically acceptable salts and solvates of said compounds, for the treatment of obesity, sub-types of anxiety, sub-types of schizophrenia and types of dementia of various origins.
-
2.发明公开NOVEL USE OF COMBINED 5-HT 1A AGONISTS AND SELECTIVE SEROTONIN REUPTAKE INHIBITORS 审中-公开联合5-HT1A激动剂和选择性血清素录音抑制剂的新用途
公开(公告)号：EP1335716A1
公开(公告)日：2003-08-20
申请号：EP01996368.5
申请日：2001-11-02
申请人： MERCK PATENT GmbH
发明人： BARTOSZYK, Gerd , SEDMAN, Ewen
IPC分类号： A61K31/00 , A61K31/496 , A61P29/00 , A61P1/00
CPC分类号： A61K31/496 , A61K31/00
摘要： The present invention relates to the use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT1A receptor agonists, in particular of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of chronic pain disorders or in treating other conditions where there is hyper-sensitization to painful signals, hyperalgesia, allodynia, enhanced pain perception, and enhanced memory of pain, as well as for the treatment of irritable bowel syndrome (IBS).
-
公开(公告)号：EP1448201B1
公开(公告)日：2007-11-28
申请号：EP02781293.2
申请日：2002-10-28
申请人： Merck Patent GmbH
CPC分类号： A61K31/496
摘要： The invention relates to the use of compounds of formula (I), wherein R , R , R and R have the designations cited in patent claim 1, and to the physiologically acceptable salts and solvates of said compounds, for the treatment of obesity, sub-types of anxiety, sub-types of schizophrenia and types of dementia of various origins.
-
4.发明授权NOVEL USE OF 1-[4-(5-CYANOINDOL-3YL)BUTYL]-4-(2-CARBAMOYLBENZOFURAN-5-YL)PIPERAZINE AND ITS PHYSIOLOGICAL ACCEPTABLE SALTS FOR THE TREATMENT OF BIPOLAR DISORDERS AND MANIA 有权1- USE [4-（5-氰基吲哚-3-基）丁基] -4-（2-氨基甲酰基 - 苯并呋喃-5-基） - 哌嗪和其生理学可接受的盐用于治疗双相疾病和MANIE的
公开(公告)号：EP1185272B1
公开(公告)日：2004-04-07
申请号：EP00935031.5
申请日：2000-05-16
申请人： MERCK PATENT GmbH
发明人： BARTOSZYK, Gerd , SEYFRIED, Christoph , VAN AMSTERDAM, Christoph , BÖTTCHER, Henning , SEDMAN, Ewen
IPC分类号： A61K31/495 , A61P25/18 , A61P25/24
CPC分类号： A61K31/496 , A61K31/00 , A61K31/495 , A61K31/497
摘要： 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
-
5.发明公开NOVEL USE OF 1-[4-(5-CYANOINDOL-3YL)BUTYL]-4-(2-CARBAMOYLBENZOFURAN-5-YL)PIPERAZINE AND ITS PHYSIOLOGICAL ACCEPTABLE SALTS 有权1- USE [4-（5-氰基吲哚-3-基）丁基] -4-（2-氨基甲酰基 - 苯并呋喃-5-基） - 哌嗪和其生理学可接受的盐用于治疗双相疾病和MANIE的
公开(公告)号：EP1185272A2
公开(公告)日：2002-03-13
申请号：EP00935031.5
申请日：2000-05-16
申请人： MERCK PATENT GmbH
发明人： BARTOSZYK, Gerd , SEYFRIED, Christoph , VAN AMSTERDAM, Christoph , BÖTTCHER, Henning , SEDMAN, Ewen
IPC分类号： A61K31/495
CPC分类号： A61K31/496 , A61K31/00 , A61K31/495 , A61K31/497
摘要： 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof is used for the manufacture of a medicament for the treatment of sub-type anxiety disorders chosen from the sub-types panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized-anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.
-
-
-
-
搜索结果
5 条记录 (耗时 0.012 秒)
